肥胖  脂肪因子与食管腺癌的研究进展

段晓峰; 唐鹏; 于振涛

doi:10.3969/j.issn.1000-8179.20130285

肥胖脂肪因子与食管腺癌的研究进展

doi: 10.3969/j.issn.1000-8179.20130285

天津医科大学肿瘤医院食管肿瘤科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室（天津市300060）

详细信息

通讯作者:
于振涛 yuzhtao@hotmail.com

计量
- 文章访问数: 20
- HTML全文浏览量: 37
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2013-03-15
- 修回日期: 2013-04-24

Research progress on obesity, adipokines, and esophageal adenocarcinoma

Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Preveution and Therapy, Tianjin, Tianjin 300060, China

More Information

Corresponding author: Zhentao YU; E-mail: yuzhtao@hotmail.com

摘要

摘要: 肥胖与肿瘤是全球两大影响健康的重要问题，肥胖增加食管腺癌的发病及死亡风险。脂肪组织能够分泌多种生物学活性的脂肪因子，如瘦素、脂联素、抵抗素等。近年研究发现脂肪因子在胃食管返流病、Barrett食管及癌变中发挥重要作用。本文就肥胖及脂肪因子与食管腺癌的研究进展进行综述。
- 食管腺癌 /
- 脂肪因子 /
- 瘦素 /
- 脂联素
Abstract: Obesity has rapidly become a pandemic and is associated with increased carcinogenesis, especially esophageal adenocarcinoma (EA). Adipose tissue is considered an endocrine organ because of its capacity to secrete a variety of adipokines, such as leptin, adiponectin, and resistin. Adipokines have recently been found to be associated with different types of chronic esophageal diseases, including gastro-esophageal reflux diseases, Barrett esophagus, and carcinogenesis. First-hand evidence supporting the inhibitory and/or active function of adipokines has been collected on human EA. This review aims to provide important insights into the potential mechanisms of adipokines in EA progression.
- esophageal adenocarcinoma /
- adipokine /
- leptin /
- adiponectin

HTML全文

参考文献(30)

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. doi: 10.3322/caac.20107
[2]	Bird-Lieberman EL, Fitzgerald RC. Early diagnosis of oesophageal cancer[J]. Br J Cancer, 2009, 101(1): 1-6. doi: 10.1038/sj.bjc.6605126
[3]	Calle EE. Obesity and cancer[J]. BMJ, 2007, 335(7630): 1107-1108. doi: 10.1136/bmj.39384.472072.80
[4]	Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets[J]. Cancer Epidemiol, 2011, 35(4): 309-319. doi: 10.1016/j.canep.2011.03.001
[5]	Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(5): 872-878. doi: 10.1158/1055-9965.EPI-05-0860
[6]	Navarro Silvera SA, Mayne ST, Risch HA, et al. Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer[J]. Ann Epidemiol, 2011, 21(7): 543-550. doi: 10.1016/j.annepidem.2010.11.019
[7]	Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma[J]. Semin Gastrointest Dis, 2003, 14(3): 128-135.
[8]	Kamat P, Wen S, Morris J, et al. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis[J]. Ann Thorac Surg, 2009, 87(2): 655-662. doi: 10.1016/j.athoracsur.2008.08.003
[9]	El-Serag HB, Kvapil P, Hacken-Bitar J, et al. Abdominal obesity and the risk of Barrett's esophagus[J]. Am J Gastroenterol, 2005, 100(10): 2151-2156. doi: 10.1111/j.1572-0241.2005.00251.x
[10]	Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity[J]. Arch Med Res, 2008, 39 (8): 715-728. doi: 10.1016/j.arcmed.2008.09.005
[11]	Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue[J]. Nature, 1994, 372 (6505): 425-432. doi: 10.1038/372425a0
[12]	Ahima RS, Osei SY. Leptin signaling[J]. Physiol Behav, 2004, 81(2): 223-241. doi: 10.1016/j.physbeh.2004.02.014
[13]	Kendall BJ, Macdonald GA, Hayward NK, et al. Leptin and the risk of Barrett's oesophagus[J]. Gut, 2008, 57(4): 448-454.
[14]	Francois F, Roper J, Goodman AJ, et al. The association of gastric leptin with oesophageal inflammation and metaplasia[J]. Gut, 2008, 57(1): 16-24.
[15]	Buttar NS, Wang KK. Mechanisms of disease: Carcinogenesis in Barrett's esophagus[J]. Nat Clin Pract Gastroenterol Hepatol, 2004, 1(2): 106-112. doi: 10.1038/ncpgasthep0057
[16]	Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation[J]. Endocrinology, 2006, 147(9): 4505-4516. doi: 10.1210/en.2006-0224
[17]	Ogunwobi OO, Beales IL. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor[J]. Br J Biomed Sci, 2008, 65(3): 121-127. doi: 10.1080/09674845.2008.11732814
[18]	Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture[J]. Mol Cell Endocrinol, 2007, 274(1-2): 60-68. doi: 10.1016/j.mce.2007.05.017
[19]	Somasundar P, Riggs D, Jackson B, et al. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms[J]. Am J Surg, 2003, 186(5): 575-578. doi: 10.1016/j.amjsurg.2003.07.017
[20]	Howard JM, Beddy P, Ennis D, et al. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma[J]. Br J Surg, 2010, 97(7): 1020-1027. doi: 10.1002/bjs.7072
[21]	Diakowska D, Krzystek-Korpacka M, Markocka-Maczka K, et al. Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract[J]. Cytokine, 2010, 51(2): 132-137. doi: 10.1016/j.cyto.2010.05.006
[22]	Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone[J]? Diabetes Care, 2003, 26(8): 2442-2450. doi: 10.2337/diacare.26.8.2442
[23]	Yoon MJ, Lee GY, Chung JJ, et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha[J]. Diabetes, 2006, 55(9): 2562-2570.
[24]	Schober F, Neumeier M, Weigert J, et al. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release[J]. Biochem Biophys Res Commun, 2007, 361(4): 968-973. doi: 10.1016/j.bbrc.2007.07.106
[25]	Rubenstein JH, Dahlkemper A, Kao JY, et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus[J]. Am J Gastroenterol, 2008, 103(6): 1358-1364. doi: 10.1111/j.1572-0241.2008.01823.x
[26]	Rubenstein JH, Kao JY, Madanick RD, et al. Association of adiponectin multimers with Barrett's oesophagus[J]. Gut, 2009, 58(12): 1583-1589. doi: 10.1136/gut.2008.171553
[27]	Kato M, Watabe K, Hamasaki T, et al. Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups[J]. J Gastroenterol, 2011, 46 (12): 1361-1367. doi: 10.1007/s00535-011-0453-3
[28]	Yildirim A, Bilici M, Cayir K, et al. Serum adiponectin levels in patients with esophageal cancer[J]. Jpn J Clin Oncol, 2009, 39(2): 92-96.
[29]	Konturek PC, Burnat G, Rau T, et al. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line[J]. Dig Dis Sci, 2008, 53(3): 597-605. doi: 10.1007/s10620-007-9922-1
[30]	Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation[J]. Mol Cell Endocrinol, 2008, 285(1-2): 43-50. doi: 10.1016/j.mce.2008.01.023